Sign In
Buy CMMB
$1.72
-0.0200 (-1.15%)
At Close: Jun 03, 2026
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Thursday, 14'th May 2026
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additi
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
08:00am, Thursday, 19'th Mar 2026
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 17'th Feb 2026
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest
04:52am, Thursday, 15'th Jan 2026
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ: CMMB - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 18
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
08:00am, Monday, 24'th Nov 2025
TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
08:00am, Thursday, 20'th Nov 2025
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a
Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.
Best Momentum Stocks to Buy for Oct. 23
11:00am, Thursday, 23'rd Oct 2025
PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.
New Strong Buy Stocks for Oct. 23: MQ, GES and More
08:06am, Thursday, 23'rd Oct 2025
MQ, GES, TRV, CMMB and PARR have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 23, 2025.
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Thursday, 21'st Aug 2025
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato
CMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South Sudan
04:05pm, Thursday, 14'th Aug 2025
Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launching an emergency response in South Sudan as compounding crises threaten thousands of lives in Upper
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
08:00am, Thursday, 14'th Aug 2025
— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug's Unique
SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential
